Imricor Medical Systems (ASX:IMR): US Launch, MRI Devices and Funding in 2026

Aditi Sarkar

02 November 2026 06:13 PM AEDT

Imricor Medical Systems (ASX:IMR): US Launch, MRI Devices and Funding in 2026

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Imricor Medical Systems, Inc. (ASX:IMR) closed at AUD 1.30 on 2 November 2026.
In its August 2026 quarterly update, Imricor Medical Systems (ASX:IMR) identified Rady Children’s Hospital in San Diego as its first US customer for NorthStar.
Imricor Medical Systems (ASX:IMR) reported second-quarter 2026 Revenue of USD 60,500, compared with USD 65,200 a year earlier.
Cash flow, execution and business-specific risks remain key monitoring points.

Imricor Medical Systems, Inc. (ASX:IMR) develops medical devices that enable cardiac procedures using magnetic resonance imaging rather than conventional X-ray guidance. Its shares closed at AUD 1.30 on 2 November 2026. During 2026 the company progressed US regulatory clearances, introduced a cardiovascular Business offering and began converting its technology into US hospital purchasing activity, while reporting limited quarterly revenue and continuing operating cash outflows.

Medical Technology and Hospital Customers

Imricor Medical Systems (ASX:IMR) supplies MRI-compatible catheters, its NorthStar mapping system and associated equipment for interventional cardiac magnetic resonance procedures. The systems are designed for use by clinical teams in specialised hospital facilities. Commercial adoption requires hospitals to invest in compatible equipment, configure workflows, train personnel and establish suitable procedural programs. Consequently, regulatory clearance alone does not necessarily result in immediate product sales, and procurement timelines are relevant when assessing growth.

US Commercial Launch and Clinical Progress

In its August 2026 quarterly update, Imricor Medical Systems (ASX:IMR) identified Rady Children’s Hospital in San Diego as its first US customer for NorthStar. It also launched Imricor Cardiovascular, targeting cardiac catheterisation procedures conducted with real-time MRI guidance. The FDA cleared paediatric label expansions for NorthStar and the Vision-MR Diagnostic Catheter. Meanwhile, the company continued its VISABL-AFL clinical trial, which supports the regulatory application for its ablation catheter. Additional approval steps and completion of trial enrolment remain necessary for the full US platform.

Quarterly Revenue, Cash Outflow and Placement

Imricor Medical Systems (ASX:IMR) reported second-quarter 2026 revenue of USD 60,500, compared with USD 65,200 a year earlier. Its quarterly net loss was approximately USD 7.4 million. Operating cash outflow was approximately USD 6.1 million, down from USD 7.9 million in the March quarter. During the period it completed an AUD 60 million Placement at AUD 1.85 per CDI. At 30 June 2026, cash and short-term investments were USD 67.5 million, with subsequent option proceeds taking the pro forma amount to approximately USD 69.6 million.

Commercial Execution and Financing Risks

Imricor Medical Systems (ASX:IMR) must turn cleared devices and prospective hospital relationships into repeatable sales. Delays in hospital procurement, clinical trial completion, device approval or installation can postpone revenue. Continued product development and US commercial expansion require spending before recurring cash receipts are established. Funding from the placement gives the company resources but does not establish that sales will cover future expenditures. The timing of revenue recognition is also affected by equipment delivery and procedure-related sales.

Imricor's disclosures draw an important distinction between regulatory clearance for selected devices and approval for its complete ablation platform. Commercial activity can begin in an approved use while other intended uses remain subject to separate regulatory procedures and trial milestones.

Hospital deployment can involve equipment acquisition, site preparation, procedural Training and clinical scheduling. As a result, the company's announcement of a prospective customer does not establish the timing of recognized revenue. Quarterly cash-flow statements provide an additional check on expenditure during expansion.

Key Insights

Imricor Medical Systems (ASX:IMR) reported a 2026 shift toward US commercial sales after regulatory milestones, with Clinical Trials still ongoing. Revenue remained limited in the June quarter and operating Cash Flow was negative. Hospital purchasing conversion, trial completion, quarterly cash use and the balance between expenditure and sales will indicate whether commercialisation is progressing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.